F.D.A. Declines to Approve MDMA Therapy, Seeking More Study

The Food and Drug Administration on Friday declined to approve MDMA-assisted therapy for the treatment of post-traumatic stress disorder, dashing the hopes of many Americans with intractable mental health conditions who are desperate for new treatments. According to Lykos Therapeutics, the company that had sought approval for the treatment, the agency said there was insufficient
F.D.A. Declines to Approve MDMA Therapy, Seeking More Study

The Food and Drug Administration on Friday declined to approve MDMA-assisted therapy for the treatment of post-traumatic stress disorder, dashing the hopes of many Americans with intractable mental health conditions who are desperate for new treatments.

According to Lykos Therapeutics, the company that had sought approval for the treatment, the agency said there was insufficient data to allow its use. The company said that the F.D.A is requesting an additional clinical trial, to continue to assess whether the drug, commonly known as Ecstasy or molly, would be safe and effective.

Had it been approved, MDMA would have become the first psychedelic compound to be regulated by federal health authorities.

Outright approval by the F.D.A. would have been a watershed moment in the decades-long effort by researchers to demonstrate the healing potential of compounds like LSD and psilocybin, the psychoactive component of so-called magic mushrooms.

,

“This is an earthquake for those in the field who thought F.D.A. approval would be a cinch,” said Michael Pollan, the best-selling author and co-founder of the UC Berkeley Center for the Science of Psychedelics. His book, “How to Change Your Mind,” helped catalyze public interest in the therapeutic potential of psychoactive compounds, demonized during the nation’s long war on drugs.

But the agency’s decision had not been entirely unexpected, after a group of independent experts convened by the F.D.A. to evaluate Lykos’s data met in June and rejected the company’s application. With regard to two central questions, the experts voted overwhelmingly that the company had not proven the treatment was effective, and that its benefits did not outweigh the risks.

Total
0
Shares
Leave a Reply
Related Posts
‘No doubt’ punch thrown by older half-brother of 11-year-old girl in ‘heat of the moment’ caused her fatal brain injury, inquest hears
Read More

‘No doubt’ punch thrown by older half-brother of 11-year-old girl in ‘heat of the moment’ caused her fatal brain injury, inquest hears

There is 'no doubt' a punch thrown by the older brother of 11-year-old girl could have caused her fatal brain injury, an inquest heard today. Falaq Babar died in hospital more than three weeks after being found on the bathroom floor of her family home in Rochdale, Greater Manchester. Her half-brother Suhail Mohammed, 23, had
Royals superstar Witt, Rockies standout Doyle named Players of the MonthRoyals superstar Witt, Rockies standout Doyle named Players of the Month
Read More

Royals superstar Witt, Rockies standout Doyle named Players of the MonthRoyals superstar Witt, Rockies standout Doyle named Players of the Month

Royals superstar Witt, Rockies standout Doyle named Players of the Month August 3rd, 2024 Brian Murphy @Spokes_Murphy Share share-square-620156 With the All-Star Game and Trade Deadline behind us, the race to October is on. But let’s quickly take one last look back to July, when we saw some players get as hot as the summer
Djokovic Beats Alcaraz For Olympic Gold—In Battle Of World’s Top-Paid Tennis Stars
Read More

Djokovic Beats Alcaraz For Olympic Gold—In Battle Of World’s Top-Paid Tennis Stars

Forbes Business Breaking Djokovic Beats Alcaraz For Olympic Gold—In Battle Of World's Top-Paid Tennis Stars Molly Bohannon Forbes Staff Molly Bohannon has been a Forbes news reporter since 2023. Following Aug 4, 2024, 11:10am EDT Share to Facebook Share to Linkedin Topline Novak Djokovic of Serbia beat Carlos Alcaraz of Spain in the gold medal